KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC. PMID 36646209 · J Thorac Oncol · 2023-May The record describes a secondary/prognostic analysis (radiomic signature development) from randomized Phase III trials (CheckMate-017, -026, -063), but the phase is not explicitly stated in the provided metadata or abstract text. The primary focus is biomarker validation, not the original primary efficacy result of the drug intervention. Therefore, eligibility cannot be fully established without confirmation of the trial phase and whether this is the primary trial report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. PMID 37034683 · medRxiv · 2023-Mar-27 The record is from a Phase III randomized oncology trial with time-to-event endpoints, but the abstract describes a secondary/biomarker analysis of MRD detection techniques (duplex sequencing vs. flow cytometry) and their prognostic value, not a report on the efficacy of a specific drug intervention. The trial (SWOG-S0106) itself involved drugs, but this publication is not a report of the trial's drug efficacy results.
S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757. PMID 36893003 · Blood · 2023-Mar-09 The publication type indicates a Phase III randomized controlled trial in oncology (multiple myeloma), but the abstract is missing, and the title/deterministic review signals provide no reliable information about a drug-containing intervention, a time-to-event efficacy endpoint, or an original formal-result report. Without an abstract or full text, key eligibility criteria (human, drug intervention, time-to-event endpoint, original result) cannot be established.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells. PMID 36534496 · Clin Cancer Res · 2023-Mar-01 The record describes a secondary biomarker analysis from a phase III trial, not the original formal result report of the randomized trial's drug intervention efficacy.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A complex communication skills training program for physicians providing advanced cancer care - content development and barriers and solutions for implementation. PMID 36919800 · J Commun Healthc · 2023-Mar The study is a randomized controlled trial in oncology, but the provided abstract describes an educational intervention (communication skills training) and its implementation barriers, not the results of a drug-containing Phase III/IIIb or Phase II/III trial with a primary time-to-event efficacy endpoint. Therefore, it does not meet the core eligibility criteria for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. PMID 36762512 · ACR Open Rheumatol · 2023-Mar The study is a Phase 3 randomized trial of a drug (guselkumab) in humans, but the disease is psoriatic arthritis, not a human malignant neoplasm. Furthermore, the primary efficacy endpoints are categorical response rates (ACR20/50, MDA) and not time-to-event outcomes like OS, PFS, DFS, EFS, RFS, TTP, or analyses with Kaplan-Meier/HR.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Internet-delivered cognitive behavioural therapy for depression and anxiety in breast cancer survivors: Results from a randomised controlled trial. PMID 36635249 · Psychooncology · 2023-Mar The record is excluded because it does not meet the key eligibility criteria: it reports on a non-drug intervention (iCBT) and lacks a time-to-event primary/key secondary efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The study is an original randomized trial in human oncology, but it is not a drug-based Phase III/IIIb or Phase II/III trial with a time-to-event endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Corrigendum to "Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial" [Eur Urol (2022)]. PMID 36503643 · Eur Urol · 2023-Mar The record is a published erratum for a screening trial. It does not meet the core criteria: it is not an original result report, it does not contain a drug intervention, and no time-to-event efficacy endpoint is established from the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparison of the cytokine adsorption ability in continuous renal replacement therapy using polyethyleneimine-coated polyacrylonitrile (AN69ST) or polymethylmethacrylate (PMMA) hemofilters: a pilot single-center open-label randomized control trial. PMID 37391846 · Eur J Med Res · 2023-Jun-30 The study is a randomized controlled trial in sepsis patients comparing two types of CRRT hemofilters (AN69ST vs. PMMA). It is not an oncology study, does not involve a drug intervention, does not report a time-to-event efficacy endpoint with Kaplan-Meier or HR, and the trial phase is not specified as Phase II/III or III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Influence of Intravenous Lidocaine Infusion on Postoperative Outcome and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Patients. A Pilot Study. PMID 37345602 · J Gastrointestin Liver Dis · 2023-Jun-22 This is a randomized, double-blind, placebo-controlled trial assessing intravenous lidocaine infusion in colorectal cancer patients. While it is an oncology study with human participants, randomized design, drug intervention, and reports time-to-event outcomes (1-year recurrence and survival), it is not eligible because: 1) The phase of the trial is not explicitly stated; it is described as a 'pilot study', which does not establish Phase III/IIIb or Phase II/III definitive status. 2) The primary focus is on postoperative recovery (pain, mobilization, hospital stay) and a biomarker (neutrophil-to-lymphocyte ratio), not a predefined primary or key secondary oncology efficacy endpoint (like OS, PFS, DFS). The 1-year recurrence and survival are reported as secondary outcomes, but the trial is not designed as a definitive oncology efficacy trial. Therefore, it does not meet the strict eligibility criteria for a definitive randomized trial with a primary/key secondary time-to-event oncology efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Pragmatica-Lung Trial to Mimic "Real-World" Conditions. PMID 37068201 · Cancer Discov · 2023-Jun-02 The abstract describes the design of a Phase III randomized trial (Pragmatica-Lung) but does not report results, including any time-to-event efficacy endpoints (OS, PFS, etc.) or specific drug interventions. It is a protocol/design paper, not an original formal-result report of a trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor. PMID 36485007 · Clin Cancer Res · 2023-Jun-01 The record describes an original, randomized, placebo-controlled Phase II trial (INVICTUS) with a primary PFS endpoint, but the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided abstract/metadata, so eligibility cannot be definitively confirmed. It meets all other criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial. PMID 37080000 · Leuk Res · 2023-Jun The study does not meet the inclusion criteria because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR), and the intervention is not a drug-containing intervention. Additionally, the phase is not explicitly established as Phase III or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. PMID 36944848 · Breast Cancer Res Treat · 2023-Jun The record is eligible for inclusion as it reports an original, randomized, drug-intervention trial in human oncology with time-to-event efficacy endpoints. However, the trial phase (Phase II/III or Phase III/IIIb) is not explicitly stated in the provided metadata or abstract, preventing a definitive 'phase3_or_definitive' confirmation. Therefore, overall eligibility is set to null pending phase verification.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation. PMID 36880836 · Am J Hematol · 2023-Jun While the record describes a randomized trial with oncology, human, drug intervention, and time-to-event efficacy endpoints, the formal trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, the record cannot be deemed definitively eligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer. PMID 37282626 · Jpn J Clin Oncol · 2023-Jul-31 The record is a review/update article discussing multiple clinical trials and their results in a narrative format. While it mentions trials that are Phase III and randomized, it does not present original, formal results (e.g., survival curves, hazard ratios) for a single, specific trial. The publication type 'Clinical Trial, Phase III' is likely a general tagging for the topic, not an indicator that this specific article is a primary results report.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Development and validation of competitive risk model for older women with metaplastic breast cancer. PMID 37452414 · BMC Womens Health · 2023-Jul-14 The record describes a retrospective prognostic model study using SEER registry data, not a clinical trial report. It lacks explicit Phase III/IIIb or Phase II/III designation, a drug-containing intervention, and a primary/key secondary time-to-event efficacy endpoint from a randomized controlled trial. The publication type 'Randomized Controlled Trial' appears to be a metadata error not supported by the abstract content.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. PMID 37058234 · Clin Cancer Res · 2023-Jul-05 The record is an updated formal result of two randomized Phase II/III trials (STAMP and STRIDE) evaluating a drug combination for an oncology indication, with OS as the primary endpoint. The specific trial phases (Phase II/III) are referenced in the trial identifiers (NCT01487863, NCT01981122) but are not explicitly stated in the provided abstract text. Eligibility cannot be definitively established without explicit confirmation of the phase being Phase III/IIIb or Phase II/III from the provided metadata, hence is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. PMID 37141547 · J Clin Oncol · 2023-Jul-01 The record is an original result report of a randomized trial in pediatric oncology (ALL) evaluating drug interventions (chemotherapy regimens with methotrexate) with primary time-to-event endpoints (EFS, OS). However, the explicit trial phase (e.g., Phase III) is not stated in the provided metadata (title, abstract, publication types, MeSH). Without clear evidence of Phase III/IIIb or Phase II/III, eligibility cannot be confirmed as per the criteria requiring explicit establishment of all criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy alone for Crohn's perianal fistulas (PISA-II): long-term outcomes of an international, multicentre patient preference, randomised controlled trial. PMID 37457118 · EClinicalMedicine · 2023-Jul The study is a randomized controlled trial in Crohn's disease (non-oncology), evaluating anti-TNF therapy ± surgical closure for perianal fistulas. The primary endpoint is radiological healing (binary outcome), not a time-to-event endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the required oncology or time-to-event efficacy endpoint criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). PMID 37422371 · Eur Urol Focus · 2023-Jul The record describes the design and rationale of a Phase 3 randomized trial in human oncology with a drug intervention, but does not report any time-to-event efficacy results, Kaplan-Meier curves, or hazard ratios. Therefore, eligibility cannot be determined.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. PMID 37245441 · Eur J Cancer · 2023-Jul Cannot establish eligibility because the original trial's phase (Phase III/IIIb or Phase II/III) is not explicitly confirmed in the provided metadata, and this report is a secondary diagnostic comparison analysis, not the primary trial result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. PMID 37105265 · Ann Oncol · 2023-Jul This is a secondary analysis of a Phase III randomized trial focusing on ctDNA biomarkers and mutational landscape, not the primary efficacy report. While the trial is Phase III, randomized, and includes time-to-event data, this specific report is a biomarker/secondary analysis of the primary trial, not the original formal result.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[TTF-1-negative lung adenocarcinoma: special features of systemic treatment]. PMID 37094793 · Pneumologie · 2023-Jul The abstract describes a randomized trial in oncology with human subjects and a drug intervention, but it is a report of an ongoing study (protocol) without presenting formal efficacy results. There is no signal of a primary or key secondary time-to-event endpoint with results, which is mandatory for inclusion in this cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study. PMID 36870797 · Eur Urol · 2023-Jul The record identifies a Phase 3b randomized trial with a drug intervention (enzalutamide and docetaxel) for prostate cancer, but lacks an abstract or full text, so the presence of a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) and whether this is an original formal-result report cannot be established from the metadata alone.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study. PMID 36791768 · Cancer Res Treat · 2023-Jul The record describes a randomized trial with a drug intervention and a time-to-event primary endpoint (PFS) in oncology. However, the phase of the trial is not explicitly stated in the provided metadata (title, abstract, publication types) as Phase III/IIIb or Phase II/III. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit confirmation of the phase from the formal report, eligibility cannot be established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study. PMID 36075994 · J Cancer Res Clin Oncol · 2023-Jul The study is a randomized, drug-intervention trial with primary time-to-event efficacy endpoints. However, the explicit trial phase (e.g., Phase III) is not stated in the provided metadata or abstract, preventing definitive eligibility confirmation.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. PMID 36067063 · J Oncol Pharm Pract · 2023-Jul The record reports safety and patient preference results from patients who switched to subcutaneous daratumumab in two phase 3 trials (ALCYONE, MAIA). It does not report the primary or key secondary time-to-event efficacy outcomes (e.g., OS, PFS) from these randomized trials. The analysis is limited to safety and preference among switchers, not a comparison of the randomized arms' efficacy.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Advances in cancer vaccines for immunotherapy of prostate cancer. PMID 36935188 · Zhong Nan Da Xue Xue Bao Yi Xue Ban · 2023-Jan-28 This is a review article, not an original report of a randomized trial. It mentions trials but does not present primary or secondary time-to-event efficacy results from a specific drug-containing intervention trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). PMID 36694252 · Trials · 2023-Jan-24 The record is a published erratum with an empty abstract. The deterministic review signals no time-to-event endpoint, no drug intervention, and cannot establish phase, human subjects, or original result status. Therefore, it does not meet the criteria for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
New reporting items and recommendations for randomized trials impacted by COVID-19 and force majeure events: a targeted approach. PMID 36760246 · Ann Transl Med · 2023-Jan-15 This is a review article (report_type: 'other') that proposes reporting guidelines based on a review of oncology trials. It is not an original clinical trial report with a drug intervention and a time-to-event efficacy endpoint. Therefore, it is ineligible.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. PMID 35833298 · Haematologica · 2023-Jan-01 The study is a human oncology randomized trial analyzing time-to-event outcomes for a drug intervention. However, the abstract does not explicitly state that the included SWOG trials (S8600, S9031, S9333, S0106, S1203) are Phase III or Phase II/III. The publication type is 'Randomized Controlled Trial' but does not specify phase. Therefore, the phase criterion cannot be definitively established from the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. PMID 36752726 · Future Oncol · 2023-Jan The record is a clinical trial protocol for a phase III randomized trial in oncology with a drug intervention, but it does not report results or explicitly identify a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR data. As a protocol, it does not meet the requirement for an original formal-result report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer. PMID 35680471 · J Formos Med Assoc · 2023-Jan The record is a title-only entry with an empty abstract, and the title indicates it is likely a review or commentary on phase III trials, not a primary result report of a single randomized trial with a time-to-event endpoint. Key criteria (randomization, time_to_event, original_result) cannot be established from the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of goal-directed fluid therapy based on plasma colloid osmotic pressure on the postoperative pulmonary complications of older patients undergoing major abdominal surgery. PMID 36849953 · World J Surg Oncol · 2023-Feb-28 The study is a randomized trial in oncology patients but does not report a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR. It assesses short-term postoperative complications, and the intervention is goal-directed fluid therapy (not a drug-containing regimen). Phase is not specified.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. PMID 36813827 · NPJ Digit Med · 2023-Feb-22 This is a published erratum for an article on a randomized phase III trial in prostate cancer. As an erratum, it is not an original report of trial results. The provided record lacks an abstract or sufficient text to verify human subjects, drug intervention, or a primary time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR). Therefore, it does not meet the criteria for an original formal-result report of a definitive randomized trial with the required endpoint.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. PMID 35906831 · Clin Infect Dis · 2023-Feb-18 The record explicitly describes a randomized trial with a primary OS endpoint in human oncology patients, but the phase (Phase III/IIIb or Phase II/III) is not stated in the provided metadata or abstract. The phase is required for eligibility and cannot be inferred, so eligibility is indeterminate.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. PMID 36108304 · Blood · 2023-Feb-16 The study is a phase 2/3 trial in acute lymphoblastic leukemia with a drug intervention (JZP458) and reports original efficacy results. However, it is not randomized and does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary efficacy endpoint is pharmacodynamic (proportion maintaining adequate nadir serum asparaginase activity).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study. PMID 36717163 · Int J Gynecol Cancer · 2023-Feb-06 The record is a protocol for an ongoing phase III randomized trial with a primary time-to-event endpoint (DFS). It is not a result report. Furthermore, the intervention arms (chemoradiation with tailored field vs. surgical staging with tailored chemoradiation) do not explicitly mention a specific drug agent, making the drug intervention criterion uncertain.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. PMID 36256912 · J Clin Oncol · 2023-Feb-01 The record meets most eligibility criteria (oncology, human, randomized, drug intervention, time-to-event primary endpoint, original result). However, the trial phase is not explicitly established in the provided metadata (title, abstract, publication types, MeSH, deterministic review signals). Therefore, the overall eligibility cannot be determined as true per the instruction to set 'is_eligible' to true only when every required criterion is explicitly established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. PMID 36625894 · Cancer Chemother Pharmacol · 2023-Feb The record describes an exposure-response analysis, which is a secondary/pharmacometric analysis, not the primary or definitive efficacy report of the CheckMate 9ER trial. While the trial is Phase III, oncology, human, involves drug intervention, and includes time-to-event endpoints, the report type is secondary. Randomization is strongly implied but not explicitly stated in the provided abstract. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Phase III results for first-line treatment for metastatic colorectal cancer. PMID 36526904 · Nat Rev Gastroenterol Hepatol · 2023-Feb The record describes an oncology, human, randomized, Phase III trial with a drug intervention and appears to be an original results report. However, the metadata contains no explicit signal of a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.), which is a required criterion for inclusion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. PMID 36517990 · Leuk Lymphoma · 2023-Feb The study is an oncology randomized controlled trial with drug intervention and phase II/III, but the provided metadata does not explicitly state a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, KM). Without this signal, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial. PMID 36422763 · Front Med · 2023-Feb The record describes a randomized trial of adjuvant chemotherapy vs. concurrent chemoradiotherapy in cervical cancer, with PFS as the primary endpoint and HR reporting. However, the trial phase is not explicitly stated as Phase III, Phase II/III, or equivalent in the provided metadata, which is required for eligibility. All other criteria are met.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Death Anxiety and Correlates in Cancer Patients Receiving Palliative Care. PMID 36067074 · J Palliat Med · 2023-Feb The study is an ancillary analysis of a randomized clinical trial of Dignity Therapy (a psychosocial intervention) in cancer patients receiving palliative care. It is not a drug intervention trial, lacks a definitive Phase III designation, and does not report a primary time-to-event efficacy endpoint such as overall survival or progression-free survival. Therefore, it does not meet the inclusion criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Wound healing after therapy of oral potentially malignant disorders with a 445-nm semiconductor laser: a randomized clinical trial. PMID 38147181 · Clin Oral Investig · 2023-Dec-26 Study is a randomized trial in an oncology precursor context, but it compares a laser device to surgery for wound healing outcomes, not a drug intervention, and does not report a time-to-event efficacy endpoint as defined for Kaplan-Meier digitization.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Nomogram and Risk Classification System Predicting the Prognosis of Patients with De Novo Metastatic Breast Cancer Undergoing Immediate Breast Reconstruction: A Surveillance, Epidemiology, and End Results Population-Based Study. PMID 38248093 · Curr Oncol · 2023-Dec-23 The record is a population-based prognostic nomogram study for breast cancer-specific survival in de novo metastatic breast cancer patients. It is not an original report of a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. The study uses a database (SEER) to build a prediction model, not to report trial results. No explicit trial phase is provided, and while it mentions chemotherapy as a factor, it is not a drug intervention trial. The time-to-event outcome (BCSS) is prognostic, not a trial efficacy endpoint. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Intraoperative cerebrospinal fluid leakage and residual tumors in endoscopic transsphenoidal surgery for pituitary adenoma: risk analysis and nomogram development. PMID 37966528 · Acta Neurochir (Wien) · 2023-Dec The record is a retrospective analysis of surgical outcomes for pituitary adenomas, which is oncology-related and human. It uses random assignment for model validation but is not a drug intervention trial, does not report a time-to-event efficacy endpoint, and is not a Phase III/IIIb or Phase II/III trial. Therefore, it is ineligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. PMID 37949086 · Lancet Oncol · 2023-Dec The study is a randomized, phase 2/3 trial of an HPV vaccine with a drug intervention, but the primary endpoint is immunogenicity (geometric mean titers), not a time-to-event efficacy endpoint (e.g., overall survival, progression-free survival). No Kaplan-Meier analysis or hazard ratio for a time-to-event outcome is reported.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan. PMID 37934081 · Acta Oncol · 2023-Dec The record is a Phase III randomized trial in oncology with a drug intervention and is an original result report. However, the provided metadata (title, publication types, mesh terms, deterministic review) does not contain any explicit signal of a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis. Without this signal, eligibility cannot be confirmed.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -